A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Major depressive disorder is a common, recurrent, disabling and costly disorder that is often severe and/or chronic, and for which non-remission on guideline concordant first-line antidepressant treatment is the norm. A sizeable percentage of patients diagnosed with MDD do not achieve full remission after receiving antidepressant treatment. How to understand or approach these 'refractory', 'TRD' or 'difficult to treat' patients need to be revisited. Treatment resistant depression (TRD) has been described elsewhere as failure to respond to adequate treatment by two different antidepressants. This definition is problematic as it suggests that TRD is a subtype of major depressive disorder (MDD), inferring a boundary between TRD and depression that is not treatment resistant. However, there is scant evidence to suggest that a discrete TRD entity exists as a distinct subtype of MDD, which itself is not a discrete or homogeneous entity. Similarly, the boundary between TRD and other forms of depression is predicated at least in part on regulatory and research requirements rather than biological evidence or clinical utility. AIM: This paper aims to investigate the notion of treatment failure in order to understand (i) what is TRD in the context of a broader formulation based on the understanding of depression, (ii) what factors make an individual patient difficult to treat, and (iii) what is the appropriate and individualised treatment strategy, predicated on an individual with refractory forms of depression? METHOD: Expert contributors to this paper were sought internationally by contacting representatives of key professional societies in the treatment of MDD - World Federation of Societies for Biological Psychiatry, Australasian Society for Bipolar and Depressive Disorders, International Society for Affective Disorders, Collegium Internationale Neuro-Psychopharmacologium and the Canadian Network for Mood and Anxiety Treatments. The manuscript was prepared through iterative editing. OUTCOMES: The concept of TRD as a discrete subtype of MDD, defined by failure to respond to pharmacotherapy, is not supported by evidence. Between 15 and 30% of depressive episodes fail to respond to adequate trials of 2 antidepressants, and 68% of individuals do not achieve remission from depression after a first-line course of antidepressant treatment. Failure to respond to antidepressant treatment, somatic therapies or psychotherapies may often reflect other factors including; biological resistance, diagnostic error, limitations of current therapies, psychosocial variables, a past history of exposure to childhood maltreatment or abuse, job satisfaction, personality disorders, co-morbid mental and physical disorders, substance use or non-adherence to treatment. Only a subset of patients not responding to antidepressant treatment can be explained through pharmacokinetic or pharmacodynamics mechanisms. We propose that non remitting MDD should be personalised, and propose a strategy of 'deconstructing depression'. By this approach, the clinician considers which factors contribute to making this individual both depressed and 'resistant' to previous therapeutic approaches. Clinical formulation is required to understand the nature of the depression. Many predictors of response are not biological, and reflect a confluence of biological, psychological, and sociocultural factors, which may influence the illness in a particular individual. After deconstructing depression at a personalised level, a personalised treatment plan can be constructed. The treatment plan needs to address the factors that have contributed to the individual's hard to treat depression. In addition, an individual with a history of illness may have a lot of accumulated life issues due to consequences of their illness, and these should be addressed in a recovery plan. LIMITATIONS: A 'deconstructing depression' qualitative rubric does not easily provide clear inclusion and exclusion criteria for researchers wanting to investigate TRD. CONCLUSIONS: MDD is a polymorphic disorder and many individuals who fail to respond to standard pharmacotherapy and are considered hard to treat. These patients are best served by personalised approaches that deconstruct the factors that have contributed to the patient's depression and implementing a treatment plan that adequately addresses these factors. The existence of TRD as a discrete and distinct subtype of MDD, defined by two treatment failures, is not supported by evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1873 · Cited by 1,525
Nanni, V., Uher, R., & Danese, A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020335 · Cited by 1,480
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181 · cited 1×
“…2013, 2015, 2017), Texas Medication Algorithm Project (TMAP) (Suehs et al. 2008), CANMAT guidelines (Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et…”
Self-citationAssociation of socioeconomic position with health behaviors and mortality
Stringhini, S. (2010) · JAMA · doi:10.1001/jama.2010.297 · Cited by 1,065 · cited 2×
“…the WFSBP guidelines (Bauer et al. 2002a, 2002b; Bauer 2007; Bauer et al. 2007, 2013, 2015, 2017), Texas Medication Algorithm Project (TMAP) (Suehs et al. 2008), CANMAT guidelines (Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh,…”
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842 · cited 3×
“…(Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et al. 2016), RANZCP (Ellis 2004; Malhi et al. 2015) and NICE guidelines (NICE Guidance 2018).”
BackgroundSelf-citationMcIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Self-citationMilev, R. V., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., Downar, J., Modirrousta, M., Patry, S., Vila-Rodriguez, F., Lam, R. W., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716660033 · Cited by 586 · cited 1×
“…(Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et al. 2016), RANZCP (Ellis 2004; Malhi et al. 2015) and NICE guidelines (NICE Guidance 2018).”
BackgroundSelf-citationParikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562 · cited 1×
“…(Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et al. 2016), RANZCP (Ellis 2004; Malhi et al. 2015) and NICE guidelines (NICE Guidance 2018).”
BackgroundSelf-citationLifestyle medicine for depression
Sarris, J., O’Neil, A., Coulson, C. E., Schweitzer, I., & Berk, M. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-107 · Cited by 450 · cited 1×
“Lifestyle psychiatry, encompassing diet, physical activity, sleep, digital technology and stress management is of increasing promise and interest (Sarris et al. 2014; Firth et al. 2019).”
BackgroundSelf-citationLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431 · cited 1×
“Functional impairment should also be investigated and tools, such as the Sheehan Disability Scale (SDS) (Sheehan et al. 1996) and the Lam Employment, Absence and Productivity Scale (LEAPS) (Lam et al. 2009) are available.”
MethodSelf-citationTreatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 2×
“Proposed definitions include failure to respond to two or more mechanistically dissimilar antidepressants (Thase 2011; McIntyre et al. 2014), with the caveat that dose and duration of treatment must be adequate (Holtzmann et al. 2016).”
BackgroundSelf-citationRavindran, A. V., Balneaves, L. G., Faulkner, G., Ortiz, A., McIntosh, D., Morehouse, R. L., Ravindran, L., Yatham, L. N., Kennedy, S. H., Lam, R. W., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716660290 · Cited by 337 · cited 1×
“…(Kennedy et al. 2009; Lam, Kennedy, et al. 2009; Kennedy et al. 2016; Lam, Kennedy, et al. 2016; Lam, McIntosh, et al. 2016; MacQueen et al. 2016; Milev et al. 2016; Parikh et al. 2016; Ravindran et al. 2016), RANZCP (Ellis 2004; Malhi et al. 2015) and NICE guidelines (NICE Guidance 2018).”
BackgroundSelf-citationWajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Self-citationLam, R. W., McIntosh, D., Wang, J., Enns, M. W., Kolivakis, T., Michalak, E. E., Sareen, J., Song, W.-Y., Kennedy, S. H., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659416 · Cited by 288
Self-citationScott, J., Leboyer, M., Hickie, I., Berk, M., Kapczinski, F., Frank, E., Kupfer, D., & McGorry, P. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.110858 · Cited by 260
Self-citationIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257 · cited 2×
“2016), as well as of its different enantiomers (Correia-Melo et al. 2020; Leal et al. 2020; Wei et al. 2020).”
BackgroundBerlim, M. T., & Turecki, G. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.009 · Cited by 249 · cited 1×
“TRD has not been identified as a discrete biological disease entity, and a universally accepted definition of TRD does not exist (Berlim and Turecki 2007; McIntyre et al. 2014) (see Table 1).”
BackgroundHistory of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder
Berk, M., Dodd, S., Callaly, P., Berk, L., Fitzgerald, P., de Castella, A. R., Filia, S., Filia, K., Tahtalian, S., Biffin, F., et al. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.027 · Cited by 217 · cited 1×
“…depressive disorder (PDD)/dysthymia, a depression secondary to a general medical condition or substance misuse, or bipolar depression where a depressive episode is the more common index episode for, and the predominant polarity of, bipolar disorder (Berk et al. 2007; Carvalho et al. 2014).”
BackgroundSelf-citationMacneil, C. A., Hasty, M. K., Conus, P., & Berk, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-111 · Cited by 203 · cited 2×
“Given the high level of heterogeneity among persons with MDD, deconstruction of their ‘depression’ diagnosis into elements of formulation may be helpful (Macneil et al. 2012).”
BackgroundSelf-citationBauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199 · cited 1×
“There are several current treatment guidelines for depression, including the WFSBP guidelines (Bauer et al. 2002a, 2002b; Bauer 2007; Bauer et al. 2007, 2013, 2015, 2017), Texas Medication Algorithm Project (TMAP) (Suehs et al. 2008), CANMAT guidelines (Kennedy et al. 2009; Lam, Kennedy, et al.…”
Self-citationCorreia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Early Identification and Intervention in Depressive Disorders: Towards a Clinical Staging Model
Hetrick, S. E., Parker, A. G., Hickie, I. B., Purcell, R., Yung, A. R., & McGorry, P. D. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000140085 · Cited by 186 · cited 1×
“Although called a staging model, the treatment algorithm model of TRD is not an illness progression staging model, where staging progresses from early symptoms to a full episode to chronic illness (Hetrick et al. 2008), and so it is important not to confuse the two.”
MethodPharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Self-citationChandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158 · cited 3×
“The Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ) (Chandler et al. 2010) is a selfreport questionnaire with good specificity for identify-”
BackgroundInfluentialBartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152 · cited 1×
“…Study of Resistant Depression identified several genetic variables associated with TRD, but interestingly found no association between CYP gene polymorphisms and TRD, suggesting that the significance of metaboliser status may be less important than other genetic polymorphisms (Bartova et al. 2019).”
BackgroundSelf-citationMcIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145 · cited 2×
“A dimensional approach (McIntyre et al. 2015), where cognitive dysfunction is recognised as a symptom domain and treatment target rather than exclusively focussing on low mood, may be a useful inclusion in the Deconstructing Depression approach.”
BackgroundSelf-citationDefining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123 · cited 3×
“Pharmacotherapeutic strategies are commonly proposed, including augmentation (Edwards et al. 2013; Carvalho et al. 2014) or combination therapy (Thomas et al. 2015), as well as other treatments including neurostimulation (including transcranial magnetic stimulation (Emond et al. 2013) and…”
BackgroundSelf-citationThomas, S. J., Shin, M., McInnis, M. G., & Bostwick, J. R. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1576 · Cited by 116 · cited 2×
“Variations of treatment algorithm -based definitions of TRD include; the Massachusetts General Hospital staging method, The European Staging Method and the Maudsley Staging Method, which differ in criteria and are described in detail elsewhere (Trevino et al. 2014).”
BackgroundMethodHarris, M. G., Kazdin, A. E., Chiu, W. T., Sampson, N. A., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Altwaijri, Y., Andrade, L. H., Cardoso, G., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1107 · Cited by 100 · cited 1×
“Lastly, a recent study emphasised the importance of persistence in treatment of depression, which showed that 93.9% of people with depression improved if they persevered with 10 treatments, however only 21.5% of patients persevered (Harris et al. 2020).”
BackgroundInfluentialSmoking and antidepressants pharmacokinetics: a systematic review
Oliveira, P., Ribeiro, J., Donato, H., & Madeira, N. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0140-8 · Cited by 60 · cited 2×
“etine, mirtazapine and trazadone due to enzyme induction (Oliveira et al. 2017).”
BackgroundWHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?: Editorial
Newport, D. J., Schatzberg, A. F., & Nemeroff, C. B. (2016) · Depression and Anxiety · doi:10.1002/da.22535 · Cited by 30
Cited by
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
Self-citationMolecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
Self-citationMcIntyre, R. S., Lipsitz, O., Lui, L. M. W., Rodrigues, N. B., Gill, H., Nasri, F., Ling, R., Teopiz, K. M., Ho, R. C., Subramaniapillai, M., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.07.035 · Cited by 21
Self-citationTripi, D., Giantesani, M., Arena, J. F., & Ferracuti, S. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1835123
Metadata
- Authors
- Dodd, S., Bauer, M., Carvalho, A. F., Eyre, H., Fava, M., Kasper, S., Kennedy, S. H., Khoo, J.-P., Lopez Jaramillo, C., Malhi, G. S., McIntyre, R. S., Mitchell, P. B., Castro, A. M. P., Ratheesh, A., Severus, E., Suppes, T., Trivedi, M. H., Thase, M. E., Yatham, L. N., Young, A. H., & Berk, M.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2020-12-08
- Volume
- 22
- Issue
- 7
- Pages
- 483-494
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W3112171960
- Cited by
- 88
- References
- 35
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.